Annual CFF
$5.00 M
-$76.85 M-93.90%
31 December 2023
Summary:
Inovio Pharmaceuticals annual cash flow from financing activities is currently $5.00 million, with the most recent change of -$76.85 million (-93.90%) on 31 December 2023. During the last 3 years, it has fallen by -$460.28 million (-98.93%). INO annual CFF is now -98.93% below its all-time high of $465.28 million, reached on 31 December 2020.INO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$660.60 K
-$32.37 M-98.00%
30 September 2024
Summary:
Inovio Pharmaceuticals quarterly cash flow from financing activities is currently $660.60 thousand, with the most recent change of -$32.37 million (-98.00%) on 30 September 2024. Over the past year, it has dropped by -$38.00 thousand (-5.44%). INO quarterly CFF is now -99.69% below its all-time high of $213.51 million, reached on 31 March 2020.INO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$24.17 M
-$38.00 K-0.16%
30 September 2024
Summary:
Inovio Pharmaceuticals TTM cash flow from financing activities is currently $24.17 million, with the most recent change of -$38.00 thousand (-0.16%) on 30 September 2024. Over the past year, it has increased by +$14.34 million (+145.99%). INO TTM CFF is now -94.81% below its all-time high of $465.28 million, reached on 31 December 2020.INO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INO Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -93.9% | -5.4% | +146.0% |
| 3 y3 years | -98.9% | +249.9% | -91.7% |
| 5 y5 years | -83.9% | -95.8% | -78.1% |
INO Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -98.9% | at low | -98.6% | +105.8% | -91.7% | +506.6% |
| 5 y | 5 years | -98.9% | at low | -99.7% | +105.8% | -94.8% | +506.6% |
| alltime | all time | -98.9% | +151.5% | -99.7% | +105.8% | -94.8% | +310.1% |
Inovio Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $660.60 K(-98.0%) | $24.17 M(-0.2%) |
| June 2024 | - | $33.03 M(-390.7%) | $24.21 M(-507.2%) |
| Mar 2024 | - | -$11.36 M(-718.2%) | -$5.94 M(-219.0%) |
| Dec 2023 | $5.00 M(-93.9%) | $1.84 M(+163.1%) | $5.00 M(-49.2%) |
| Sept 2023 | - | $698.60 K(-75.8%) | $9.82 M(-24.1%) |
| June 2023 | - | $2.88 M(-778.8%) | $12.94 M(-75.6%) |
| Mar 2023 | - | -$424.70 K(-106.4%) | $52.99 M(-35.2%) |
| Dec 2022 | $81.84 M(-61.3%) | $6.67 M(+74.9%) | $81.84 M(-33.3%) |
| Sept 2022 | - | $3.81 M(-91.1%) | $122.77 M(+3.6%) |
| June 2022 | - | $42.94 M(+51.1%) | $118.52 M(+50.0%) |
| Mar 2022 | - | $28.42 M(-40.3%) | $79.02 M(-62.6%) |
| Dec 2021 | $211.50 M(-54.5%) | $47.59 M(<-9900.0%) | $211.50 M(-27.3%) |
| Sept 2021 | - | -$440.80 K(-112.8%) | $290.84 M(+0.4%) |
| June 2021 | - | $3.44 M(-97.9%) | $289.59 M(-29.8%) |
| Mar 2021 | - | $160.90 M(+26.8%) | $412.67 M(-11.3%) |
| Dec 2020 | $465.28 M(+341.5%) | $126.94 M(-7588.6%) | $465.28 M(+33.7%) |
| Sept 2020 | - | -$1.70 M(-101.3%) | $347.99 M(-4.7%) |
| June 2020 | - | $126.52 M(-40.7%) | $365.26 M(+52.2%) |
| Mar 2020 | - | $213.51 M(+2113.6%) | $240.03 M(+127.7%) |
| Dec 2019 | $105.40 M(+239.6%) | $9.65 M(-38.1%) | $105.40 M(-4.3%) |
| Sept 2019 | - | $15.58 M(+1103.9%) | $110.15 M(+0.9%) |
| June 2019 | - | $1.29 M(-98.4%) | $109.13 M(-1.2%) |
| Mar 2019 | - | $78.88 M(+448.0%) | $110.42 M(+255.8%) |
| Dec 2018 | $31.04 M(-67.6%) | $14.39 M(-1.2%) | $31.04 M(+87.9%) |
| Sept 2018 | - | $14.56 M(+463.6%) | $16.52 M(-77.3%) |
| June 2018 | - | $2.58 M(-610.3%) | $72.84 M(-22.8%) |
| Mar 2018 | - | -$506.40 K(+306.1%) | $94.36 M(-1.4%) |
| Dec 2017 | $95.69 M(+1128.9%) | -$124.70 K(-100.2%) | $95.69 M(-1.0%) |
| Sept 2017 | - | $70.89 M(+194.1%) | $96.69 M(+220.5%) |
| June 2017 | - | $24.10 M(+2816.2%) | $30.17 M(+253.1%) |
| Mar 2017 | - | $826.40 K(-5.0%) | $8.54 M(+9.7%) |
| Dec 2016 | $7.79 M(-90.8%) | $870.30 K(-80.1%) | $7.79 M(+10.0%) |
| Sept 2016 | - | $4.37 M(+76.3%) | $7.08 M(+59.6%) |
| June 2016 | - | $2.48 M(+3465.0%) | $4.43 M(-94.7%) |
| Mar 2016 | - | $69.50 K(-56.4%) | $84.42 M(+0.1%) |
| Dec 2015 | $84.35 M(+16.4%) | $159.40 K(-90.8%) | $84.35 M(-1.2%) |
| Sept 2015 | - | $1.73 M(-97.9%) | $85.36 M(+1.5%) |
| June 2015 | - | $82.47 M(>+9900.0%) | $84.13 M(+3173.0%) |
| Mar 2015 | - | $0.00(-100.0%) | $2.57 M(-96.5%) |
| Dec 2014 | $72.46 M(+37.5%) | $1.17 M(+133.9%) | $72.46 M(-4.4%) |
| Sept 2014 | - | $498.70 K(-44.9%) | $75.82 M(-27.0%) |
| June 2014 | - | $905.10 K(-98.7%) | $103.92 M(+0.9%) |
| Mar 2014 | - | $69.89 M(+1445.6%) | $103.02 M(+95.5%) |
| Dec 2013 | $52.69 M(+889.5%) | $4.52 M(-84.2%) | $52.69 M(+0.8%) |
| Sept 2013 | - | $28.60 M(>+9900.0%) | $52.27 M(+110.0%) |
| June 2013 | - | $5900.00(-100.0%) | $24.89 M(+0.0%) |
| Mar 2013 | - | $19.56 M(+377.2%) | $24.89 M(+367.3%) |
| Dec 2012 | $5.33 M(-81.0%) | $4.10 M(+234.5%) | $5.33 M(+8.4%) |
| Sept 2012 | - | $1.23 M(>+9900.0%) | $4.91 M(+33.2%) |
| June 2012 | - | $0.00(0.0%) | $3.69 M(-0.0%) |
| Mar 2012 | - | $0.00(-100.0%) | $3.69 M(-86.8%) |
| Dec 2011 | $28.01 M | $3.69 M(>+9900.0%) | $28.01 M(+7.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | $0.00(-100.0%) | $26.11 M(+1.5%) |
| June 2011 | - | $100.00(-100.0%) | $25.72 M(+75.2%) |
| Mar 2011 | - | $24.32 M(+1258.0%) | $14.68 M(-251.4%) |
| Dec 2010 | -$9.69 M(-133.9%) | $1.79 M(-550.0%) | -$9.69 M(-15.7%) |
| Sept 2010 | - | -$398.00 K(-96.4%) | -$11.50 M(-165.6%) |
| June 2010 | - | -$11.04 M(>+9900.0%) | $17.54 M(-38.7%) |
| Mar 2010 | - | -$50.50 K(+156.3%) | $28.59 M(-0.0%) |
| Dec 2009 | $28.60 M(+135.2%) | -$19.70 K(-100.1%) | $28.60 M(-26.7%) |
| Sept 2009 | - | $28.65 M(>+9900.0%) | $39.02 M(+221.4%) |
| June 2009 | - | $15.80 K(-142.7%) | $12.14 M(+0.1%) |
| Mar 2009 | - | -$37.00 K(-100.4%) | $12.12 M(-0.3%) |
| Dec 2008 | $12.16 M(-25.4%) | $10.40 M(+489.0%) | $12.16 M(+589.0%) |
| Sept 2008 | - | $1.76 M(>+9900.0%) | $1.76 M(>+9900.0%) |
| June 2008 | - | $0.00(0.0%) | $6100.00(-100.0%) |
| Mar 2008 | - | $0.00(0.0%) | $16.20 M(-0.6%) |
| Dec 2007 | $16.30 M(+14.9%) | $0.00(-100.0%) | $16.30 M(-46.6%) |
| Sept 2007 | - | $6100.00(-100.0%) | $30.51 M(-0.0%) |
| June 2007 | - | $16.20 M(>+9900.0%) | $30.51 M(+113.5%) |
| Mar 2007 | - | $99.40 K(-99.3%) | $14.30 M(+0.7%) |
| Dec 2006 | $14.19 M(-3.4%) | $14.20 M(>+9900.0%) | $14.19 M(-4.2%) |
| Sept 2006 | - | $15.00 K(-167.6%) | $14.81 M(+1.1%) |
| June 2006 | - | -$22.20 K(+825.0%) | $14.66 M(+0.8%) |
| Mar 2006 | - | -$2400.00(-100.0%) | $14.54 M(-1.0%) |
| Dec 2005 | $14.69 M(+25.9%) | $14.82 M(<-9900.0%) | $14.69 M(+3355.9%) |
| Sept 2005 | - | -$139.00 K(+1.0%) | $425.10 K(-8.7%) |
| June 2005 | - | -$137.60 K(-194.6%) | $465.40 K(-95.6%) |
| Mar 2005 | - | $145.40 K(-73.9%) | $10.56 M(-9.5%) |
| Dec 2004 | $11.67 M(-25.5%) | $556.30 K(-663.6%) | $11.67 M(-38.2%) |
| Sept 2004 | - | -$98.70 K(-101.0%) | $18.87 M(-29.4%) |
| June 2004 | - | $9.96 M(+692.8%) | $26.72 M(+57.8%) |
| Mar 2004 | - | $1.26 M(-83.8%) | $16.94 M(+8.0%) |
| Dec 2003 | $15.67 M(+241.2%) | $7.76 M(+0.1%) | $15.67 M(+98.6%) |
| Sept 2003 | - | $7.75 M(+4452.9%) | $7.89 M(+5267.5%) |
| June 2003 | - | $170.20 K(-3034.5%) | $147.00 K(-96.6%) |
| Mar 2003 | - | -$5800.00(-75.1%) | $4.26 M(-7.2%) |
| Dec 2002 | $4.59 M(+293.5%) | -$23.30 K(-494.9%) | $4.59 M(-0.5%) |
| Sept 2002 | - | $5900.00(-99.9%) | $4.62 M(+0.5%) |
| June 2002 | - | $4.29 M(+1212.4%) | $4.59 M(+1456.1%) |
| Mar 2002 | - | $326.50 K(-1924.0%) | $295.20 K(-94.0%) |
| Dec 2001 | $1.17 M(-79.7%) | - | - |
| Sept 2001 | - | -$17.90 K(+33.6%) | $4.94 M(-0.7%) |
| June 2001 | - | -$13.40 K(-100.3%) | $4.98 M(-13.3%) |
| Mar 2001 | - | $5.02 M(<-9900.0%) | $5.74 M(+210.2%) |
| Mar 2001 | $5.74 M(-56.3%) | - | - |
| Dec 2000 | - | -$43.50 K(-371.9%) | $1.85 M(-15.7%) |
| Sept 2000 | - | $16.00 K(-97.9%) | $2.19 M(-7.7%) |
| June 2000 | - | $750.90 K(-33.4%) | $2.38 M(-81.9%) |
| Mar 2000 | $13.13 M(+90.2%) | $1.13 M(+275.6%) | $13.13 M(+9.4%) |
| Dec 1999 | - | $300.00 K(+50.0%) | $12.00 M(+2.6%) |
| Sept 1999 | - | $200.00 K(-98.3%) | $11.70 M(+1.7%) |
| June 1999 | - | $11.50 M | $11.50 M |
| Mar 1999 | $6.90 M | - | - |
FAQ
- What is Inovio Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals annual CFF year-on-year change?
- What is Inovio Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals quarterly CFF year-on-year change?
- What is Inovio Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals TTM CFF year-on-year change?
What is Inovio Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of INO is $5.00 M
What is the all time high annual CFF for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high annual cash flow from financing activities is $465.28 M
What is Inovio Pharmaceuticals annual CFF year-on-year change?
Over the past year, INO annual cash flow from financing activities has changed by -$76.85 M (-93.90%)
What is Inovio Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of INO is $660.60 K
What is the all time high quarterly CFF for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high quarterly cash flow from financing activities is $213.51 M
What is Inovio Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, INO quarterly cash flow from financing activities has changed by -$38.00 K (-5.44%)
What is Inovio Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of INO is $24.17 M
What is the all time high TTM CFF for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high TTM cash flow from financing activities is $465.28 M
What is Inovio Pharmaceuticals TTM CFF year-on-year change?
Over the past year, INO TTM cash flow from financing activities has changed by +$14.34 M (+145.99%)